Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05238779 · ClinicalTrials.gov registry record
An Integrative Model for Palliative Care in End-Stage Liver Disease
A clinical trial, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- 28
- Enrollment target
NCT05238779: Completed study, sponsored by Virginia Commonwealth University.
NCT05238779 is a clinical trial that has completed, run by Virginia Commonwealth University. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05238779 has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- 28 participants
- Enrollment target
Study Summary
The purpose of this research study is to understand the impact of palliative care in ESLD on quality of life, emergency room or hospital visits, and on care provider burden, and to work to develop the best way to provide palliative care in ESLD.
Primary Outcome
Edmonton Symptom Assessment System (ESAS) - participants rate the intensity of common symptoms on 0-10 scale with 0= no symptom and 10=worst symptom imaginable. Scores range from 0 to 90 with higher scores indicating worse symptoms.
Interventions
- OTHER Standard of care including palliative care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2022-01-06 |
| Est. Completion | 2022-12-12 |
What the finished NCT05238779 record still lists
NCT05238779 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 28 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Standard of care including palliative care is the first listed.
NCT05238779 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05238779 about?
NCT05238779 is a clinical study titled "An Integrative Model for Palliative Care in End-Stage Liver Disease". The purpose of this research study is to understand the impact of palliative care in ESLD on quality of life, emergency room or hospital visits, and on care provider burden, and to work to develop the best way to provide palliative care in ESLD.
What is the current status of trial NCT05238779?
This trial is currently completed. The enrollment target is 28 participants. The study started on 2022-01-06. Estimated completion is 2022-12-12.
What interventions are being tested in trial NCT05238779?
The interventions under investigation include: Standard of care including palliative care (OTHER).
Who is sponsoring clinical trial NCT05238779?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI